TRDA Quote, Financials, Valuation and Earnings

Edgewise Therapeutics has a net margin of -71.7% compared to Entrada Therapeutics's net margin of --. Entrada Therapeutics's return on equity of 17.06% beat Edgewise Therapeutics's return on equity of --.

Entrada Therapeutics has a consensus price target of --, signalling upside risk potential of 50.5%. On the other hand Edgewise Therapeutics has an analysts' consensus of $49.43 which suggests that it could grow by 66.88%. Given that Edgewise Therapeutics has higher upside potential than Entrada Therapeutics, analysts believe Edgewise Therapeutics is more attractive than Entrada Therapeutics.

Entrada Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Edgewise Therapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Entrada Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edgewise Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entrada Therapeutics pays -- of its earnings as a dividend. Edgewise Therapeutics pays out -- of its earnings as a dividend.

Entrada Therapeutics quarterly revenues are $19.6M, which are larger than Edgewise Therapeutics quarterly revenues of --. Entrada Therapeutics's net income of -$14M is higher than Edgewise Therapeutics's net income of -$34.1M. Notably, Entrada Therapeutics's price-to-earnings ratio is 11.04x while Edgewise Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entrada Therapeutics is 2.94x versus -- for Edgewise Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regenxbio has a net margin of -71.7% compared to Entrada Therapeutics's net margin of -246.3%. Entrada Therapeutics's return on equity of 17.06% beat Regenxbio's return on equity of -69.62%.

Entrada Therapeutics has a consensus price target of --, signalling upside risk potential of 50.5%. On the other hand Regenxbio has an analysts' consensus of $37.64 which suggests that it could grow by 408.6%. Given that Regenxbio has higher upside potential than Entrada Therapeutics, analysts believe Regenxbio is more attractive than Entrada Therapeutics.

Entrada Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regenxbio has a beta of 1.243, suggesting its more volatile than the S&P 500 by 24.251%.

Entrada Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regenxbio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entrada Therapeutics pays -- of its earnings as a dividend. Regenxbio pays out -- of its earnings as a dividend.

Entrada Therapeutics quarterly revenues are $19.6M, which are smaller than Regenxbio quarterly revenues of $24.2M. Entrada Therapeutics's net income of -$14M is higher than Regenxbio's net income of -$59.6M. Notably, Entrada Therapeutics's price-to-earnings ratio is 11.04x while Regenxbio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entrada Therapeutics is 2.94x versus 4.19x for Regenxbio. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -71.7% compared to Entrada Therapeutics's net margin of 7.2%. Entrada Therapeutics's return on equity of 17.06% beat Sarepta Therapeutics's return on equity of 12.48%.

Entrada Therapeutics has a consensus price target of --, signalling upside risk potential of 50.5%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.10 which suggests that it could grow by 51.85%. Given that Sarepta Therapeutics has higher upside potential than Entrada Therapeutics, analysts believe Sarepta Therapeutics is more attractive than Entrada Therapeutics.

Entrada Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

Entrada Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entrada Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Entrada Therapeutics quarterly revenues are $19.6M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. Entrada Therapeutics's net income of -$14M is lower than Sarepta Therapeutics's net income of $33.6M. Notably, Entrada Therapeutics's price-to-earnings ratio is 11.04x while Sarepta Therapeutics's PE ratio is 79.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entrada Therapeutics is 2.94x versus 7.48x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -71.7% compared to Entrada Therapeutics's net margin of 37.71%. Entrada Therapeutics's return on equity of 17.06% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Entrada Therapeutics has a consensus price target of --, signalling upside risk potential of 50.5%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $493.61 which suggests that it could grow by 20.93%. Given that Entrada Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Entrada Therapeutics is more attractive than Vertex Pharmaceuticals.

Entrada Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.364, suggesting its less volatile than the S&P 500 by 63.631%.

Entrada Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Entrada Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Entrada Therapeutics quarterly revenues are $19.6M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Entrada Therapeutics's net income of -$14M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Entrada Therapeutics's price-to-earnings ratio is 11.04x while Vertex Pharmaceuticals's PE ratio is 25.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Entrada Therapeutics is 2.94x versus 10.00x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.